Lipid Nanoparticles Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	98 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19224188

Best Price Guarantee
Price	from $4,850
Length	98 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19224188

Lipid Nanoparticles Market

Growth Factors of Lipid Nanoparticles Market

The lipid nanoparticles market size was valued at USD 880.0 million in 2023, and the market is now projected to grow from USD 997.2 million in 2024 to USD 2823.4 million by 2032, exhibiting a CAGR of 13.9% during the forecast period of 2024-2032.

The market also witnessed fair share of revenue growth in the year 2020, mainly contributed by the increasing usage of Lipid Nanoparticles (LNPs) for vaccines’ delivery. These nanoparticles help in delivery of delicate mRNA used in COVID-19 vaccines into human cells to facilitate gene therapies. Pfizer and Moderna employ LNPs in their mRNA COVID-19 vaccines launched on the market. It is for this reason that the demand for LNPs has risen with pharma companies leveraging them in the pharmaceutical sector.

Site-specific drug delivery systems remain imperative in personalized medicines about improving treatment outcomes. LPN along with liposome and niosomes are used in different therapeutic segments, for example oncology and neurology. Nanotechnology based drug delivery system enhances the selectivity of the administered drug to deliver the therapy to the required site successfully. Its application is relevant for the development of personalized medicine approaches.

Lipid nanoparticles are ideal in gene therapy for diseases of genetic origin since they are much safer than viral proteins. It can bring nucleic acids of any sort into the cells with improved therapeutical options. Also, their synthesis is cost effective and fast owing to the convenience of targeting ligands that enable selective targeting in gene delivery applications. This capability greatly enhances the possibility of genetic approaches to therapy.

Comprehensive Analysis of Lipid Nanoparticles Market

The lipid nanoparticles market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly presents a detailed local analysis based on the forces such as supply and demand which define the industry. These segmentations are methodically segregated by type analysis, by application analysis and by end-user analysis. By type analysis include Solid Lipid Nanoparticles (SLNs), Nanostructured Lipid Carriers (NLCs), others. By application analysis include therapeutics, research. By end-user analysis include pharmaceutical & biotechnology companies, academic & research Institutes, others.

The North America region lead the lipid nanoparticles market share by benefitting a market size of USD 577.7 million in 2023 due to robust presence of the major players.

The top players have a significant responsibility in the healthcare industry for confirming industrial prospectus growth and determining the market trends. These players include, Merck KGaA, Evonik Industries AG, Gattefossé, Precision NanoSystems, IOI Oleo GmbH these market players provide a level-playing competitive landscape.

In July 2023, Cytiva launched NanoAssemblr, a specialized system for the clinical and commercial production of lipid nanoparticle medicines.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 13.9% from 2024-2032

Unit Value (USD Million)

Segmentation By Type

Solid Lipid Nanoparticles (SLNs)
Nanostructured Lipid Carriers (NLCs)
Others

By Application

Therapeutics
Research

By End-user

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others

By Geography

North America (By Type, By Application, By End-user, and By Country)
U.S.
Canada
Europe (By Type, By Application, By End-user, and By Country/Sub-region)
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
Asia Pacific (By Type, By Application, By End-user, and By Country/Sub-region)
China
Japan
India
Australia
Southeast Asia
Rest of Asia Pacific
Rest of the World (By Type, By Application, and By End-user)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. New Product Launches, By Key Players; 4.2. Key Industry Developments- Mergers, Acquisitions & Partnerships; 4.3. Recent Advances in Drug Delivery Using Lipid Nanoparticles; 4.4. Impact of COVID-19 on the Market
5. Global Lipid Nanoparticles Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Type; 5.1.1. Solid Lipid Nanoparticles (SLNs); 5.1.2. Nanostructured Lipid Carriers (NLCs); 5.1.3. Others; 5.2. Market Analysis, Insights and Forecast – By Application; 5.2.1. Therapeutics; 5.2.2. Research; 5.3. Market Analysis, Insights and Forecast – By End-user; 5.3.1. Pharmaceutical & Biotechnology Companies; 5.3.2. Academic & Research Institutes; 5.3.3. Others; 5.4. Market Analysis, Insights and Forecast – By Region; 5.4.1. North America; 5.4.2. Europe; 5.4.3. Asia Pacific; 5.4.4. Rest of the World
6. North America Lipid Nanoparticles Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Type; 6.1.1. Solid Lipid Nanoparticles (SLNs); 6.1.2. Nanostructured Lipid Carriers (NLCs); 6.1.3. Others; 6.2. Market Analysis, Insights and Forecast – By Application; 6.2.1. Therapeutics; 6.2.2. Research; 6.3. Market Analysis, Insights and Forecast – By End-user; 6.3.1. Pharmaceutical & Biotechnology Companies; 6.3.2. Academic & Research Institutes; 6.3.3. Others; 6.4. Market Analysis, Insights and Forecast – By Country; 6.4.1. U.S.; 6.4.2. Canada
7. Europe Lipid Nanoparticles Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Type; 7.1.1. Solid Lipid Nanoparticles (SLNs); 7.1.2. Nanostructured Lipid Carriers (NLCs); 7.1.3. Others; 7.2. Market Analysis, Insights and Forecast – By Application; 7.2.1. Therapeutics; 7.2.2. Research; 7.3. Market Analysis, Insights and Forecast – By End-user; 7.3.1. Pharmaceutical & Biotechnology Companies; 7.3.2. Academic & Research Institutes; 7.3.3. Others; 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 7.4.1. U.K.; 7.4.2. Germany; 7.4.3. France; 7.4.4. Italy; 7.4.5. Spain; 7.4.6. Scandinavia; 7.4.7. Rest of Europe
8. Asia Pacific Lipid Nanoparticles Market Analysis, Insights and Forecast, 2019-2032: 8.1. Market Analysis, Insights and Forecast – By Type; 8.1.1. Solid Lipid Nanoparticles (SLNs); 8.1.2. Nanostructured Lipid Carriers (NLCs); 8.1.3. Others; 8.2. Market Analysis, Insights and Forecast – By Application; 8.2.1. Therapeutics; 8.2.2. Research; 8.3. Market Analysis, Insights and Forecast – By End-user; 8.3.1. Pharmaceutical & Biotechnology Companies; 8.3.2. Academic & Research Institutes; 8.3.3. Others; 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.4.1. China; 8.4.2. Japan; 8.4.3. India; 8.4.4. Australia; 8.4.5. Southeast Asia; 8.4.6. Rest of Asia Pacific
9. Rest of the World Lipid Nanoparticles Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Type; 9.1.1. Solid Lipid Nanoparticles (SLNs); 9.1.2. Nanostructured Lipid Carriers (NLCs); 9.1.3. Others; 9.2. Market Analysis, Insights and Forecast – By Application; 9.2.1. Therapeutics; 9.2.2. Research; 9.3. Market Analysis, Insights and Forecast – By End-user; 9.3.1. Pharmaceutical & Biotechnology Companies; 9.3.2. Academic & Research Institutes; 9.3.3. Others
10. Competitive Analysis: 10.1. Global Market Share Analysis (2023); 10.2. Company Profiles; 10.2.1. Merck KGaA; 10.2.1.1. Overview; 10.2.1.2. Products & Services; 10.2.1.3. SWOT Analysis; 10.2.1.4. Recent Developments; 10.2.1.5. Strategies; 10.2.1.6. Financials (Based on Availability); 10.2.2. Evonik Industries AGS; 10.2.2.1. Overview; 10.2.2.2. Products & Services; 10.2.2.3. SWOT Analysis; 10.2.2.4. Recent Developments; 10.2.2.5. Strategies; 10.2.2.6. Financials (Based on Availability); 10.2.3. Gattefossé; 10.2.3.1. Overview; 10.2.3.2. Products & Services; 10.2.3.3. SWOT Analysis; 10.2.3.4. Recent Developments; 10.2.3.5. Strategies; 10.2.3.6. Financials (Based on Availability); 10.2.4. Precision NanoSystems; 10.2.4.1. Overview; 10.2.4.2. Products & Services; 10.2.4.3. SWOT Analysis; 10.2.4.4. Recent Developments; 10.2.4.5. Strategies; 10.2.4.6. Financials (Based on Availability); 10.2.5. IOI Oleo GmbH; 10.2.5.1. Overview; 10.2.5.2. Products & Services; 10.2.5.3. SWOT Analysis; 10.2.5.4. Recent Developments; 10.2.5.5. Strategies; 10.2.5.6. Financials (Based on Availability)